LILes Irwig

Les Irwig

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Les Irwig has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    EARLY CRT MONITORING USING TIME-DOMAIN OPTICAL COHERENCE TOMOGRAPHY DOES NOT ADD TO VISUAL ACUITY FOR PREDICTING VISUAL LOSS IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION TREATED WITH INTRAVITREAL RANIBIZUMAB

    by Katy J. L. Bell, Andrew Hayen, Paul Glasziou, Andrew S. Mitchell, Maria Farris, Jonathan Wright, Hans-Peter Duerr, Paul Mitchell, Les Irwig

    Our primary purpose was to assess the clinical (predictive) validity of central retinal thickness (CRT) and best corrected visual acuity (BCVA) at 1 week and 1 month after starting treatment with ranibizumab for central retinal vein occlusion. The authors also assessed detectability of response to treatment. The authors used data from 325 participants in the CRUISE study, which included measurement of time-domain CRT and BCVA at baseline, 1 week, 1 month, and 6 months postrandomization. Analysis of covariance models were fitted to assess clinical validity, and distributions of change were constructed to assess detectability of response. There was no evidence that 1-week CRT, and very strong evidence that 1-week BCVA were associated with baseline-adjusted BCVA at 6 months (P = 0.17 and P < 0.001, respectively). There was strong evidence that both 1-month CRT and 1-month BCVA were associated with baseline-adjusted 6-month BCVA (P = 0.005 and P < 0.001, respectively), but simultaneous adjustment found evidence of independent association only for BCVA (P = 0.71 and P < 0.001 for CRT and BCVA, respectively). Detectability of response tended to be higher for CRT than BCVA at 1 week and 1 month but by 6 months these were equivalent for CRT and BCVA. In this study, BCVA monitoring of treated central retinal vein occlusion patients seemed more informative than time-domain optical coherence tomography monitoring.


  • The association of surgical margins and local recurrence in women with ductal carcinoma in situ treated with breast-conserving therapy: A meta-analysis.

    by Michael Luke Marinovich, Lamiae Azizi, Petra Macaskill, Les Irwig, Monica Morrow, Lawrence J. Solin, Nehmat Houssami

    1020 Background: There is no consensus on what constitutes adequate negative margins in breast-conserving surgery (BCS) for ductal carcinoma in-situ(DCIS). We systematically review the evidence on surgical margins in BCS for DCIS. Methods: Study-level meta-analysis of studies reporting local recurrence (LR) relative to microscopic margin status and threshold distance for negative margins. LR proportion was modelled using random-effects logistic meta-regression (frequentist) that dichotomised data using one margin distance, and network meta-analysis (Bayesian) that allows for multiple margin distances per study, adjusting for follow-up time. Results: Based on 33 studies (LR in 865 of 7,883), theodds of LR were associated with margin status (logistic: odds ratio (OR) 0.53 for negative vs positive/close [P0.40). Predicted probabilities of LR at 10 years were 18.1% (>0 or 1mm), 10.1% (2mm), 8.5% (3 or 5mm), and 11.7% (10mm). In the network analysis, ORs relative to positive margins for 2mm (0.32), 3mm (0.30) and 10mm (0.32) showed similar reductions in the odds of LR that were greater than for >0 or 1mm (0.45). There was weak evidence of lower odds at 2mm compared to >0 or 1mm (Relative OR=0.72, 95% credible interval [CrI] 0.47-1.08), and no evidence of a difference between 2mm and 10mm (Relative OR=0.99, 95% CrI 0.61-1.64). Adjustment for covariates (age; median recruitment year; and proportions with radiotherapy, endocrine therapy, or high grade DCIS), and analyses based only on studies using whole-breast radiotherapy, did not change findings. Conclusions: Negative margins in BCS for DCIS reduce the odds of LR; however, minimum margins distances above 2mm are not significantly associated with further reduced odds of LR in women receiving radiation.

  • Open Access

    A self administered reliable questionnaire to assess lower bowel symptoms

    by Barbara-Ann Adelstein, Les Irwig, Petra Macaskill, Peter H Katelaris, David B Jones, Les Bokey


    • 1 December 2007
      • Vol. 36  (12) , 1065-9

    GPs want tailored, user friendly evidence summaries--a cross sectional study in New South Wales.

    by Lyndal J Trevena, Les Irwig, Anna Isaacs, Alexandra Barratt

    This study aimed to measure the use of, and barriers to, using evidence among general practitioners since computerisation of general practice; GP preference for patient involvement in health care decisions; and GPs' preferred strategies to increase the use of evidence. A cross sectional, open ended telephone survey was conducted with 107 (out of 155) New South Wales GPs randomly selected from the New South Wales Medical Board register. The survey sought self report to open ended questions about information sources informing decisions, perceived barriers to using evidence, and suggested strategies to improve clinical decisions, plus Degner scale for patient involvement. Evidence based sources remained the least likely to be used for informing decisions about patient care (23.4%). Opinion based sources were most commonly used (50.5%), with industry sponsored sources second (27.1%). Rural GPs were more likely to use opinion based sources (OR=1.55, 95% CI: 1.00-2.40). The most common perceived barriers were 'a lack of time' (22.0%), 'a lack of evidence or conflicting evidence' (13.1%), 'not knowing where to look' (10.3%) and 'not being able to tailor evidence to individual patients' (9.3%). The majority of GPs (72.0%) preferred patients to have some role in decision making. The most common suggestions for improving decision making were 'simply formatted evidence summaries' (28.0%) and 'mechanisms for tailoring evidence with individual patients' (13.1%). The use of evidence based sources for clinical decision making in general practice remains limited. Potential strategies to overcome this should focus on providing more user friendly evidence summaries, involving patients in evidence based decision making, and finding mechanisms to tailor evidence to individual patients.


  • Open Access

    Observed Differences in Diagnostic Test Accuracy between Patient Subgroups: Is It Real or Due to Reference Standard Misclassification?

    by Corné Biesheuvel, Les Irwig, Patrick Bossuyt

    Before a new test is introduced in clinical practice, its accuracy should be assessed. In the past decade, researchers have put an increased emphasis on exploring differences in test sensitivity and specificity between patient subgroups. If the reference standard is imperfect and the prevalence of the target condition differs among subgroups, apparent differences in test sensitivity and specificity between subgroups may be caused by reference standard misclassification. We provide guidance on how to determine whether observed differences may be explained by reference standard misclassification. Such misclassification may be ascertained by examining how the apparent sensitivity and specificity change with the prevalence of the target condition in the subgroups.


  • Informed choice for screening: implications for evaluation

    by Les Irwig, Kirsten McCaffery, Glenn Salkeld, Patrick Bossuyt

    Value all benefits and harms Evidence from randomised trials that screening reduces mortality is necessary but not sufficient to justify screening. Decisions should be based on an assessment of all the benefits and harms, not only of the screening test but also of follow up tests and treatments. As the UK criteria state, the screening programme must be clinically, socially, and ethically acceptable to the public and the benefits outweigh the harm.3 A holistic approach to evaluation requires studies to identify the benefits and harms perceived by consumers and clinicians. Harms include: Complications of investigation of screen detected abnormalities Unexpected effects, such as increased morbidity and mortality from side effects of screening or subsequent management Overdetection—the identification of disease that would not have presented during the person's lifetime, and Psychosocial effects. Some harms or downsides may seem trivial, but, unlike the benefits, occur soon after screening and are common. For example, biennial mammographic screening has been estimated to avert only two deaths in 1000 women aged 50-59 over 10 years but requires 5000 screens, 242 recalls, and 64 women to have at least one biopsy.5 Moreover, five women will have a ductal carcinoma in situ detected, some of which may never have progressed if left untreated. This information may lead some people to decide that the downsides of screening outweigh avoidance of longer term serious but rare outcomes.6 Consultation about screening policy between policy makers and an informed public is essential. The public can be involved through methods such as citizen juries, deliberative panels, and round table discussions with community members.7 Community surveys among representative samples can provide policy makers with useful information about how benefits are valued against harms in the population.6 8 9 Preferences can be measured directly: “Given the benefits and harms, would you prefer to be screened or not screened?” or through utility measurement techniques that assess individuals' preferences through specific trades or gambles (choices) associated with the benefits and harms of screening.


  • Evaluating new screening tests for breast cancer

    by Les Irwig, Nehmat Houssami, Bruce Armstrong, Paul Glasziou

    Footnotes Funding Supported in part by programme grant 211205 from the Australian National Health and Medical Research Council and a University of Sydney Medical Foundation Program Grant. Competing interests None declared. Research p 689 and also Letters p 727


  • Accuracy of Diagnostic Tests Read With and Without Clinical Information

    by Clement T. Loy, Les Irwig

    Review from JAMA — Accuracy of Diagnostic Tests Read With and Without Clinical Information — A Systematic Review — ContextAlthough it is common practice to read tests with clinical information, whether this improves or decreases the accuracy of test reading is uncertain.ObjectiveTo determine whether diagnostic tests are more accurate when read with clinical information or without it.Data SourcesMEDLINE search (1966-December 2003) extended by search of reference lists and articles citing the articles retrieved (Web of Science, 1985-December 2003).Study SelectionAll articles comparing the accuracy of tests read twice by the same readers, once without and once with clinical information, but otherwise under identical conditions. Only articles that reported sensitivity and specificity or receiver operating characteristic (ROC) curves were included.Data ExtractionData were extracted by one author and reviewed independently by the other. When the data were difficult to interpret, differences were resolved by discussion.Data SynthesisSixteen articles met the inclusion criteria. Eleven articles compared areas under ROC curves for tests read with and without clinical information, and 5 compared only sensitivity and specificity. Ten articles used actual clinical information; 6 used constructed clinical information that was plausible. Overall, clinical information improved test reading accuracy although the effect was smaller in the articles using actual clinical information when compared with those using constructed clinical information. There were no instances in which clinical information resulted in significant reduction in test reading accuracy. In some instances, improved test reading accuracy came from improved sensitivity without loss of specificity.ConclusionsAt least for the tests examined, the common practice of reading diagnostic tests with clinical information seems justified. Future studies should be designed to investigate the best way of providing clinical information. These studies should also give an estimate of the accuracy of clinical information used, display ROC curves with identified data points, and include a wider range of diagnostic tests.


  • Exfoliative cytology as a diagnostic test for basal cell carcinoma: a meta-analysis

    by S. Bakis, L. Irwig, G. Wood, D. Wong

    Background Exfoliative cytology is only occasionally used in clinical practice to diagnose basal cell carcinoma (BCC). Objectives To systematically review the literature examining exfoliative cytology as a diagnostic tool for BCC and to meta‐analytically summarize the accuracy of this test. Methods Diagnostic test meta‐analysis. A computerized database search was made of MEDLINE (1966–2000) and EMBASE (1950–2000) using appropriately indexed terms. Hand searches of relevant journals were made. Bibliographies of relevant articles were further explored. Histopathology was used as the reference standard. A summary receiver–operating characteristic curve analysis was performed using the statistical package Meta‐Test version 0·6 (J. Lau, New England Medical Center, Boston, MA, U.S.A., 1997). Results Eight primary studies (seven English language and one Italian language) fulfilled the inclusion criteria. The pooled sample included 1261 BCCs. These studies varied greatly in methodological quality and were, in general, poor. A meta‐analysis showed the pooled sensitivity to be high at 97%[95% confidence interval (CI) 94–99]. Consequently, only 3% of BCCs included were misdiagnosed as non‐BCC by cytology. The corresponding pooled specificity was 86% (95% CI 80–91). Conclusions Exfoliative cytology probably has a high diagnostic accuracy for BCC. However, large, better designed and better reported studies are needed to ascertain the true accuracy of this technique. In the interim, this test should be considered in specific subgroups of patients in whom even a 2‐mm punch biopsy may be considered inappropriate, e.g. a cosmetically sensitive site in a young person. Similarly, it should be considered when a BCC is to be treated without a diagnostic biopsy being taken, e.g. with cryotherapy.